PUBLISHER: BCC Research | PRODUCT CODE: 2131473
PUBLISHER: BCC Research | PRODUCT CODE: 2131473
The global market for liquid biopsy with emphasis on cancer is expected to grow from $4.1 billion in 2026 and is projected to reach $8 billion by the end of 2031, at a compound annual growth rate (CAGR) of 14.1% during the forecast period of 2026 to 2031.
The report provides an overview of the global liquid biopsy with an emphasis on cancer market and analyzes market trends. It includes global revenue ($ million), using 2025 as the base year, estimated data for 2026, and projected data from 2026 through 2031.
The report segments the market by indication, technology, biomarker type, and application. By indication, the study includes lung cancer, breast cancer, colorectal cancer, prostate cancer, and other cancers. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. Based on biomarker type, the report covers circulating nucleic acids, circulating tumor cells (CTCs), exosomes, and circulating proteins. For application, the report includes therapy guidance, therapy monitoring, early cancer screening, and recurrence monitoring. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, with a focus on key countries in these regions.
The report focuses on the key driving trends and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and highlighting the leading global liquid biopsy with an emphasis on cancer companies. It also includes a dedicated section on company profiles that covers overviews, key financials, product portfolios, and recent developments for major companies.